NCT02494921View on ClinicalTrials.gov

LEE011 (Ribociclib) in Combination With Docetaxel Plus Prednisone in mCRPC

PHASE1/PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

November 20, 2015

Primary Completion Date

July 30, 2021

Study Completion Date

July 30, 2021

Conditions
Prostate Cancer
Interventions
DRUG

Docetaxel-PNP

Given IV

DRUG

Ribociclib

Given Orally

DRUG

Prednisone

Given Orally

DRUG

Filgrastim

Given IV

Trial Locations (6)

48109

University of Michigan Comprehensive Cancer Center, Ann Arbor

55455

University of Minnesota Masonic Cancer Center, Minneapolis

60611

Northwestern University, Chicago

60637

University of Chicago Comprehensive Cancer Center, Chicago

94143

University of California, San Francisco, San Francisco

02912

Brown University, Providence

Sponsors

Collaborators (1)

Novartis
All Listed Sponsors
collaborator

Novartis

INDUSTRY

lead

Rahul Aggarwal

OTHER